Back to Search Start Over

Prevalence of Metabolic Syndrome and Associated Factors in a Cohort of Individuals With Treatment-Resistant Depression

Authors :
Godin, Ophelia
Bennabi, Djamila
Yrondi, Antoine
Richieri, Raphaëlle
D’amato, Thierry
Bellivier, Franck
Bougerol, Thierry
Horn, Mathilde
Camus, Vincent
Courtet, Philippe
Doumy, Olivier
Genty, Jean Baptiste
El-Hage, Wissam
Haesebaert, Frédéric
Holtzmann, Jérôme
Lançon, Christophe
Leboyer, Marion
Llorca, Pierre Michel
Maruani, Julia
Moliere, Fanny
Samalin, Ludovic
Schmitt, Laurent
Stéphan, Florian
Vaiva, Guillaume
Walter, Michel
Aouizerate, Bruno
Haffen, Emmanuel
Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)
Fondation FondaMental [Créteil]
Université Bourgogne Franche-Comté [COMUE] (UBFC)
Laboratoire de Neurosciences Intégratives et Cliniques - UFC (UR 481) (NEURO)
Université de Franche-Comté (UFC)
Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)
Toulouse Neuro Imaging Center (ToNIC)
Université Toulouse III - Paul Sabatier (UT3)
Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)
Hôpital de la Conception [CHU - APHM] (LA CONCEPTION)
Centre Hospitalier le Vinatier [Bron]
Neurobiologie et Psychiatrie
Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Optimisation thérapeutique en Neuropsychopharmacologie (OPTeN (UMR_S_1144 / U1144))
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)
Grenoble Institut des Neurosciences (GIN)
Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Centre Hospitalier Universitaire [Grenoble] (CHU)
Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 (SCALab)
Université de Lille-Centre National de la Recherche Scientifique (CNRS)
CHU Trousseau [Tours]
Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)
Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
Institut Mondor de Recherche Biomédicale (IMRB)
Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours )
Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo)
CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])
Université Paris Descartes - Faculté de Médecine (UPD5 Médecine)
Université Paris Descartes - Paris 5 (UPD5)
CHU Toulouse [Toulouse]
Hopital de Bohars - CHRU Brest (CHU - BREST )
Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)
Hôpital Charles Perrens
Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Laboratoire de Neurosciences Intégratives et Cliniques - UFC (EA 481) (NEURO)
Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Purpan [Toulouse]
CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse]
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)
Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193 (SCALab)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10
Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)
Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Toulouse Mind & Brain Institut (TMBI)
Université Toulouse - Jean Jaurès (UT2J)
Université de Toulouse (UT)-Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3)
Université de Toulouse (UT)-Université Toulouse - Jean Jaurès (UT2J)
Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3)
Université de Toulouse (UT)
Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)
Centre hospitalier Charles Perrens [Bordeaux]
Source :
The Journal of clinical psychiatry, The Journal of clinical psychiatry, 2019, 80 (6), ⟨10.4088/JCP.19m12755⟩
Publication Year :
2019
Publisher :
HAL CCSD, 2019.

Abstract

International audience; BACKGROUND:The aim of this study was to estimate the prevalence of metabolic syndrome (MetS) and its components in a cohort of French patients with treatment-resistant depression (TRD) and to determine correlations with sociodemographic, clinical, and treatment-related factors.METHODS:From 2012 to 2018, 205 patients who met DSM-IV criteria for major depressive episode with moderate-to-severe symptoms (Montgomery-Asberg Depression Rating Scale score ≥ 20), and at least Stage II resistance according to Thase and Rush criteria were enrolled in the FondaMental Advanced Centers of Expertise in Resistant Depression (FACE-DR) cohort. Data on sociodemographic and clinical characteristics, lifestyle information, and treatment and comorbidities were collected, and a blood sample was drawn. MetS was defined according to the criteria of the International Diabetes Federation.RESULTS:Overall, 38% of individuals with TRD met criteria for MetS. The frequency of MetS was significantly higher in men than in women only for patients aged 40 years or older (46.3% vs 35.2%, P = .0427). Moreover, whereas the management for diabetes was good, less than one-third of the patients with high blood pressure or dyslipidemia were treated for these conditions. Multivariate analysis showed that individuals with abnormal plasma c-reactive protein levels had a 3-fold increased risk (95% CI, 1.5-5.2) of having MetS, independent of other potential confounders.CONCLUSION:The prevalence of MetS is higher in patients with TRD than in those with other psychiatric disorders and characterized by a considerable undertreatment of some components of MetS in this population. Diagnosis and treatment of the components of MetS should be systematically performed to prevent the occurrence of cardiovascular diseases in patients with TRD. These findings highlight the need for integrated care, with more interaction and coordination between psychiatrists and primary care providers.

Details

Language :
English
Database :
OpenAIRE
Journal :
The Journal of clinical psychiatry, The Journal of clinical psychiatry, 2019, 80 (6), ⟨10.4088/JCP.19m12755⟩
Accession number :
edsair.dedup.wf.001..a0e6f8dc7be36561a91b7d913750a3a2